Epizyme to Participate in Leerink Partners 7th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 07, 2018 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 2:00 p.m. ET on Wednesday, Feb. 14, 2018 in New York City.

To access the live webcast of Epizyme's presentation, please visit the Events & Presentations page within the Investor page of the website at www.epizyme.com. A replay of the webcast will be available on the Epizyme website for 60 days following the conference.

About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company is also developing a novel G9a program and its next development candidate, EZM8266, is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them. For more information, visit www.epizyme.com.

Contacts:
Cheya Pope, Epizyme, Inc.
[email protected]
617-229-7561

Monique Allaire, THRUST IR
[email protected]
617-895-9511